The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial
Abstract
OBJECTIVE: Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the skin that causes permanent disability and aesthetic damage. This study was undertaken to assess the safety and efficacy of methotrexate (MTX) in the treatment of juvenile localized scleroderma. METHODS: In this double-blind study, patients with active juvenile localized scleroderma were randomized (2:1) to receive oral MTX (15 mg/m², maximum 20 mg) or placebo once weekly, for 12 months or until treatment failure. Both groups received oral prednisone (1 mg/kg/day, maximum 50 mg) for the first 3 months. A target lesion was evaluated clinically, with infrared thermography and using a computerized scoring system with skin score rate (SSR) evaluation. Response to treatment was defined as the absence of new lesions, SSR ≤ 1, and a decrease in lesion temperature of at least 10% compared to baseline. Treatment failure was defined as the occurrence of new lesions, SSR > 1, or increased lesion temperature. All analyses were done on the intent-to-treat population. RESULTS: Of the 85 patients screened, 70 (ages 6-17 years) were randomized (46 to the MTX group, 24 to the placebo group). The mean disease duration was 2.3 years. After an initial response in all patients, disease relapsed in 15 MTX-treated patients (32.6%) and 17 placebo-treated patients (70.8%) (P < 0.005). New lesions appeared in 3 MTX-treated patients (6.5%) versus 4 placebo-treated patients (16.7%). The mean SSR decreased from 1 to 0.79 in the MTX group and increased from 1 to 1.1 in the placebo group, and the mean target lesion temperature decreased by 44.4% in the MTX group versus 12.1% in the placebo group. Twenty-six patients in the MTX group (56.5%) and 11 patients in the placebo group (45.8%) developed mild side effects related to treatment. None of the side effects were severe enough to necessitate treatment discontinuation. CONCLUSION: Our findings indicate that MTX is efficacious in the treatment of juvenile localized scleroderma and is well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of health status in children with juvenile rheumatoid arthritis
Singh, G., Athreya, B. H., Fries, J. F., & Goldsmith, D. P. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371209 · Cited by 838
Cited by
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14458 · Cited by 261
Localized scleroderma: clinical spectrum and therapeutic update
Careta, M. F., & Romiti, R. (2015) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20152890 · Cited by 259
Metadata
- Authors
- Zulian, F., Martini, G., Vallongo, C., Vittadello, F., Falcini, F., Patrizi, A., Alessio, M., Torre, F. L., Podda, R. A., Gerloni, V., Cutrone, M., Belloni-Fortina, A., Paradisi, M., Martino, S., & Perilongo, G.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-06-29
- Volume
- 63
- Issue
- 7
- Pages
- 1998-2006
- ISSN
- 0004-3591 (ISSN-L)
- OpenAlex
- W2016759483
- Cited by
- 216
- References
- 1
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1002/art.30264
- The paper
- Zulian, F., Martini, G., Vallongo, C., Vittadello, F., Falcini, F., Patrizi, A., Alessio, M., Torre, F. L., Podda, R. A., Gerloni, V., Cutrone, M., Belloni-Fortina, A., Paradisi, M., Martino, S., & Perilongo, G. (2011). Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.30264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.